Product Information
ABIRTEGA 250 MG TABLET is a generic product labeled by CivicaScript LLC, priced at $0.7741 per EA under NDC 82249001112. Its NADAC has been published 52 times since Oct 8, 2025.
FDA first approved this application on Oct 31, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
CivicaScript LLCNDC
82249001112
Classification
Generic
Dosage Form
TABLET
Route
ORAL; ORAL
Effective Date
9/23/2026
Active Ingredients
ABIRATERONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA208339FDA Approved
10/31/2018
TE Code
AB
On Market Since
11/23/2018
Pharmacological Classes
Price Statistics
The NADAC for ABIRTEGA 250 MG TABLET has been published 52 times since Oct 8, 2025, and over the history we have for it it has declined 27.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7741 per EA |
|---|---|
| All-time high | $1.0638 (Oct 15, 2025) |
| All-time low | $0.7741 (Sep 23, 2026) |
| 52-week high | $1.0638 |
| 52-week low | $0.7741 |
| Median price | $0.8430 |
| Average price | $0.8706 |
| Largest weekly change | -7.6% (Dec 17, 2025) |
| Weeks tracked | 52 |
| Tracking since | Oct 8, 2025 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
CivicaScript LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Abiraterone acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cytochrome P450 17A1 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ABIRTEGA 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ABIRTEGA 250 MG TABLET, manufactured by CivicaScript LLC, is $0.7741 per EA (NDC 82249001112), effective Sep 30, 2026.
How has the price of ABIRTEGA 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for ABIRTEGA 250 MG TABLET has declined 27.2%. It has been tracked across 52 weekly CMS publications since Oct 8, 2025.
What are the highest and lowest recorded NADAC prices for ABIRTEGA 250 MG TABLET?
Since Oct 8, 2025, the NADAC for ABIRTEGA 250 MG TABLET has ranged from a low of $0.7741 (Sep 23, 2026) to a high of $1.0638 (Oct 15, 2025), with a median of $0.8430 per EA.
Are there cheaper alternatives to ABIRTEGA 250 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ABIRTEGA 250 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ABIRTEGA 250 MG TABLET?
ABIRTEGA 250 MG TABLET (NDC 82249001112) is labeled by CivicaScript LLC, and CMS classifies it as a generic product.